Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Merck & Co/MSD has agreed to buy Pandion for ... and is vying to come to market along with other IL-2-based therapies, notably Eli Lilly and Nektar Therapeutics’ phase 2 candidate LY3471851 ...

In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese's candy, call himself an 'old fart' when asked about career plans, get real about the ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Organon (OGN – Research Report) today. The company’s shares opened ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

Citi reinstated its coverage of Eli Lilly & Co. (NYSE: LLY) with a Buy rating and a target price of $1,060 per share in a ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...